Mr. Scott Cormack has more than two decades of experience in the biotechnology industry in executive management and venture capital. Scott has been President and CEO since August 2008, when OncoGenex Technologies Inc. completed a reverse takeover of Sonus Pharmaceuticals, Inc. to become OncoGenex Pharmaceuticals, Inc. Scott has led OncoGenex through significant corporate milestones, including private financings, leading the company from pre-clinical studies to completion of multiple Phase 2 clinical trials, initiation of Phase 3 trials and development of a robust pipeline. Scott was a co-founder of OncoGenex Technologies Inc., now a wholly owned subsidiary, where he served as President and a member of the Board of Directors since May 2000 and as Chief Executive Officer since February 2002. From 1998 to 2001, Scott served as Vice President of Milestone Medica Corporation, a seed venture capital firm investing in life sciences opportunities and joint venture between RBC Technology Ventures Inc. and Research Corporation Technologies. While at Milestone Medica, Scott served as interim President, Chief Executive Officer and Chairman of the Board of Directors of Salpep Biotechnology Inc., an asthma and inflammation biotechnology company, from 2000 to 2001. From 1995 to 1998, Scott served as Chief Operating Officer of NeuroSpheres Ltd, a neural stem cell biotechnology company. He was President and founder of For Tomorrow, a sole proprietorship engaged in business consulting, from 1991 to 1999. From 1986 to 1988, Scott served as Territory Manager of Vetrepharm Inc. (now Bioniche Life Sciences, Inc.), a biopharmaceutical company developing products for human and animal health markets, and from 1988 to 1991 he served as its Technology Manager, Immunomodulators. Scott holds a B.S. degree from the University of Alberta.
Dr. Jacobs is Executive Vice President and Chief Medical Officer at OncoGenex. She received her Ph.D. from Washington State University and her MD from the University of Washington Medical School. She has over twenty years of biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, Phase 1-4 clinical trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance.
Dr. Krieger has served as Vice President, Regulatory Affairs at OncoGenex since 2005. Her 30 years of experience in regulatory and clinical affairs includes 29 years at five biotechnology companies in Seattle. Most recently, she spent six years at Corixa Corporation as Vice-President, Regulatory Affairs. There she worked with Dr. Jacobs, and the clinical/regulatory team obtained Canadian approval for Melacine, a vaccine for the treatment of melanoma, as well as two US approvals for BEXXAR, a radioimmunotherapy for non-Hodgkin's lymphoma. Prior to Corixa, she was at NeoRx, where she led the regulatory group developing two oncology products: one for the treatment of non-Hodgkin's lymphoma and the second for multiple myeloma. She spent seven years at CellPro, Inc. where she worked with Dr. Jacobs to obtain two approvals from the FDA for the CEPRATE ® SC, a stem cell selection device. The first approval was based on data from patients with breast cancer and the second demonstrated the utility of the device in tumor removal in patients with multiple myeloma. Her first position in Seattle was at Genetic Systems Corporation (currently owned by BioRad Laboratories) where she was Vice President, Regulatory, Clinical and Quality Assurance at the time of her departure. During her nine years there she led a team that obtained approval for blood banking tests for HIV-1, HIV-2 and hepatitis, as well as approval of other tests for infectious disease. She received an undergraduate degree from Vassar College, a Ph.D from Rutgers University and an MBA from the Darden School at the University of Virginia.
Dr. Patricia Stewart serves as OncoGenex' Vice President of Clinical Development and previously as a Senior Medical Director. Prior to joining the company in 2005, she was a Senior Medical Director at Corixa Corporation. Patricia is Board Certified in Medical Oncology with 23 years of experience in teaching, clinical care and clinical research. She also served as a faculty member in Medical Oncology at the Fred Hutchinson Cancer Research Center and the University of Washington. She holds a B.A. degree from University of Buffalo, and an MA and MD from University of West Virginia.
Ms. Wyrick has served as Principal Accounting Officer since February 2013, and as Senior Director, Finance since June 2012. Susan served as the Director, Site Controller at Emergent BioSolutions Inc. from November 2010 to June 2012. From March 2006 to October 2010, she served as the Controller at Trubion Pharmaceuticals, Inc., which was acquired by Emergent BioSolutions Inc. in October 2010. Prior to March 2006, Susan served in senior financial positions at publicly-held biotechnology companies. She received a B.A. in Business Administration from the University of Washington and has passed the CPA exam.
Jaime Welch was appointed Vice President, Marketing and Corporate Communications in January 2012. Over the past decade, Jaime has held various sales and marketing positions with a specific concentration in Genitourinary Oncology. Prior to joining Oncogenex in July 2010, Jaime was the Global Marketing Director at Pfizer, Inc. responsible for in-line and pipeline strategic development of Sutent. She has also served in various Oncology Senior Marketing Management positions at Novartis Oncology and Abbott Laboratories. She began her pharmaceutical career as a Lupron Depot Sales Representative for TAP Pharmaceuticals in 2000. Jaime holds a degree in Communications from the University of Illinois.
© 2004-2011 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.